COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,026 Articles (22,627 medRxiv, 8,399 bioRxiv)

Most recent first Previous |  Page 128: Articles 1271-1280  | Next

Nirmatrelvir-Resistant Mutations in SARS-CoV-2 Mpro Enhance Host Immune Evasion via Cleavage of NF-κB Essential Modulator
Thomas, M., Hughes, T.
10.1101/2024.10.18.619137 — Posted: 2024-10-19
Phosphorylation Toggles the SARS-CoV-2 Nucleocapsid Protein Between Two Membrane-Associated Condensate States
Favetta, B., Wang, H., Cubuk, J., Barai, M., Ramirez, C., Gormley, A. J., Murthy, S., Soranno, A., Shi, Z., Schuster, B. S.
10.1101/2024.10.17.618867 — Posted: 2024-10-18
Effects of the COVID-19 pandemic on TB outcomes in the United States: a Bayesian analysis
Swartwood, N. A., Cohen, T., Marks, S. M., Hill, A. N., Beeler Asay, G. R., Self, J., Feng, P.-J. I., Horsburgh, C. R., Salomon, J. A., Menzies, N. A.
10.1101/2024.10.17.24315683 — Posted: 2024-10-18
Humoral waning kinetics against SARS-CoV-2 is dictated by disease severity and vaccine platform
Tong, X., Kellman, B., Avendano, M.-J., Mendu, M., Hsiao, J. C., Serrano, E., Garcia-Salum, T., Muena, N., Pardo-Roa, C., Morales, M., Levican, J., Salinas, E., Cardenas-Caceres, S., Riquelme, A., Tischler, N. D., Lauffenburger, D. A., Alter, G., P. McNamara, R., Medina, R. A.
10.1101/2024.10.17.24315607 — Posted: 2024-10-18
Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19
Hao, T., Ryan, G. E., Lydeamore, M., Cromer, D., Wood, J., McVernon, J., McCaw, J., Shearer, F. M., Golding, N.
10.1101/2024.10.17.24314397 — Posted: 2024-10-18
Hypoxia as a predictor of mortality among patients admitted with COVID-19 disease in three referral hospitals in Kenya, October 2020 to December 2021
Waruru, A., Wambua, J. M., Mbai, J., Otieno, F. V., Mwangome, M., Munyua, P., Waruiru, W., Jonnalagadda, S., Ngunu, C., Muange, A. K., Otieno, J., Onyango, D., Muturi, N., Njoroge, A.
10.1101/2024.10.17.24315667 — Posted: 2024-10-18
Imaging, Pulmonary Function, and Histopathologic Findings of Persistent Fibrosis in a Longitudinal Cohort Three Years after Severe COVID-19 Infection
Murphy, S. O., McGroder, C. F., Salvatore, M. M., D'Souza, B. M., Capaccione, K. M., Saqi, A., Shaikh, F., Benesh, S., Zhang, D., Baldwin, M. R., Garcia, C. K.
10.1101/2024.10.16.24315602 — Posted: 2024-10-17
Identification of undetected SARS-CoV-2 infections by clustering of Nucleocapsid antibody trajectories
Zwerwer, L. R., Peto, T. E. A., Pouwels, K. B., Walker, A. S., COVID-19 Infection Survey team
10.1101/2024.10.17.24315650 — Posted: 2024-10-17
Religion, Politics, and Policy Related to Age-Adjusted Cancer, Heart Disease, Infant Mortality and COVID-19 Death Rates, U.S. States 2018-2021
Robertson, L. S.
10.1101/2024.10.13.24315408 — Posted: 2024-10-17
Virological characteristics of the SARS-CoV-2 XEC variant
Kaku, Y., Okumura, K., Kawakubo, S., Uriu, K., Chen, L., Kosugi, Y., Uwamino, Y., Begum, M. M., Leong, S., Ikeda, T., Sadamasu, K., Asakura, H., Nagashima, M., Yoshimura, K., The Genotype to Phenotype Japan (G2P-Japan) Consortium, , Ito, J., Sato, K.
10.1101/2024.10.16.618773 — Posted: 2024-10-17

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).